Immutep Discontinues Lung Cancer Drug Trial Due to Futility Analysis.

Immutep will discontinue a phase three trial of its efti drug for first-line non-small cell lung cancer after a futility analysis. The decision comes despite efti's positive performance in other clinical trials. Immutep says it will focus on its ongoing phase two studies and other pipeline programs.